Transcather aortic valve implantation (TAVI) has become a safe and indispensable
treatment option for patients with severe symptomatic aortic stenosis who are at high surgical risk.
Recently, outcomes after TAVI have improved significantly and TAVI has emerged as a qualified
alternative to surgical aortic valve replacement in the treatment of intermediate risk patients and
greater adoption of this procedure is to be expected in a wider patients population, including
younger patients and low surgical risk patients. However since the aortic valve has close spatial
proximity to the conduction system, conduction anomalies are frequently observed in TAVI. In this
article, we aim to review the key aspects of pathophysiology, current incidence, predictors and
clinical association of conduction anomalies following TAVI.